Business Wire

TX-MAVENIR

11.2.2020 14:02:08 CET | Business Wire | Press release

Share
Mavenir and MUGLER Collaborate to Deliver Mavenir End-to-End 5G Private Networks in Germany

Mavenir, the industry's only end-to-end cloud-native 4G/5G network software provider for CSPs, has announced collaboration and joint go-to-market with MUGLER, a leading and well-established neutral system integrator for telco networks in Germany, to deliver Mavenir’s end-to-end 5G solutions including 5G vRAN, 5G Core & Digital Enablement Platform to the German Enterprise & Industry Market, enabled by the German Government’s Private Networks initiative and the allocation of spectrum for private enterprise and industry use.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005394/en/

Mavenir will offer its full portfolio of 4G and 5G solutions for the German Private Networks market to address the needs of Enterprises, Industries and Service Providers. Mugler will act as go to market partner for Mavenir as well as a value-added reseller including systems integration and local operation and support. In addition, Mugler has secured a private networks license from BNetzA (the German frequency regulator) and will deploy an end-to-end 5G system on its own campus at Oberlungwitz (Saxony, Germany). This network will be used for advanced enterprise use cases such as AGVs for logistics, AR/VR, IoT, Video, Broadcast and Secure Communications for Mugler’s enterprise needs, as well as a showcase and testbed for end customers.

Jointly, the companies will address the growing business opportunity for private networks for the Industry, Media, Health, Public Authorities and Service Provider segments and customers.

A Comprehensive Private Networks Solution for Enterprises and Industries

The German Government’s private networks initiative has allocated spectrum in the 3.7-3.8 GHz band for enterprises and industries to build their own mobile networks in environments such as campuses, venues, offices, factories and ports etc.

Mavenir’s OpenRAN vRAN encompasses 4G and 5G radio access, and the disaggregated RAN approach extends virtualization to the edge of the network and provides strategic differentiation by enabling multisource Remote Radio Units (RRUs) to interwork with the virtualized, containerized, Cloud Base Band software over ethernet Fronthaul (FH), using the O-RAN open interface overcoming the traditional constraints of the proprietary walled garden specifications used by the other traditional equipment vendors.

Mavenir’s 5G Core solution , based on cloud-native principles, can be retrofitted on EPCs and encompasses all the major 5G core elements, and these functions are implemented as micro-services in containers. The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobile Core’ solution that supports both 4G and 5G subscribers. In addition, the Mavenir 5G Core supports all Standalone (SA) and Non-Standalone (NSA) options.

Mavenir’s Digital Enablement platform allows Private Network operators to create a seamless way of abstracting out the complexity of the underlying network, and create a digital app store for enterprise and industry applications – thereby empowering an ecosystem of developers, service providers, technology companies, enterprises and industries to create applications to power digitalization with 5G.

This end-to-end 5G system, based on cloud-first and open architecture principles, is highly suited to address both mass scale private enterprise use cases as well as bespoke high-end use cases for advanced industries. The solution can be delivered as on-prem “network-in-a-box”, cloud-based “Network-as-a-Service” or Hybrid models.

With Mugler’s advanced services those networks can be deployed as turn-key solutions anywhere in Germany and beyond. Furthermore, Mugler’s Telco mplete® - Process covers the whole lifecycle of telco networks and infrastructure with all managed services, including end to end network design and planning, systems integration, deployment, support, maintenance, repair and field service 365/24/7.

Quotes

“As 5G use cases are emerging, together with Mugler, we are bringing our 4G/5G virtualized portfolio of solutions to the German market for quick and easy deployments,” said Aniruddho Basu, Mavenir’s SVP/GM of Emerging Business. “Mavenir’s OpenRAN vRAN and Converged Mobile Core solutions provide a cost-efficient approach to addressing the rising need for private networks for enterprises, industries and service providers.”

“Private networks will revolutionize a lot of industries. They will have an enormous leverage for digitization,” said Fabian Berger, Mugler’s Director Local Networks. “To deploy and operate those networks flexibly and cost effectively, OpenRAN and virtualized networks are up-and-coming. We see Mavenir as a strong partner to be able to quickly develop and deploy customized private networks for different industries and customers.”

About Mavenir

Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve webscale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at www.mavenir.com

About Mugler

Mugler is a medium-sized company based and mainly active in Germany. Since the foundation of our company in 1990, we have become a well-established and leading service provider and neutral system integrator for telecommunication networks and infrastructure in Germany. Today 320 employees implement our slogan “from idea to network” with our full-service Telco mplete®-Process, covering the complete lifecycle of all kinds of telecommunication infrastructure including network design and planning, systems integration, deployment, maintenance, operation and support.

With this and our long lasting know-how we are able to provide and maintain sustainable networks to all kinds of customers, from the large German CSPs (mobile and fixed) to public authorities, as well as large and smaller companies.

Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.

Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye